Lead Product(s) : Digoxin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Gets FDA Nod for Digoxin Tablets
Details : Digoxin tablets which is inhibiting Na-K ATPase, indicated for the treatment of mild to moderate heart failure in adults, increases myocardial contractility in pediatric patients with heart failure.
Product Name : Lanoxin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Digoxin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
